NovaDel Pharma Inc. announced the issuance of a new patent by the European Patent Office covering the use of multiple classes of drugs in oral sprays. European Patent No. 1,275,374 covers the use of analgesics, alkaloids and nicotine for the preparation of buccal sprays with non-polar solvents that would be absorbed through the oral mucosa. The patent is applicable in 17 countries throughout Europe for a term of twenty years.

According to a NovaDel press release, the company maintains an extensive worldwide portfolio of intellectual property rights for select compounds using its pioneering oral spray delivery system. The company now boasts eight patents issued in the US, three patents in Canada and 68 patents issued throughout Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden and Switzerland. Additionally, NovaDel has over 90 patents pending around the globe.

NovaDel also announced that one of its manufacturers has filed for Chapter 11 bankruptcy protection in US Bankruptcy Court. The company reported that it is taking all necessary steps to ensure that any limited assets of NovaDel at the manufacturer's facility are protected. NovaDel expects no material effect on the Company's outlook due to the situation and reported that NitroMist, a nitroglycerin oral spray, is the only NovaDel product manufactured by the vendor. NovaDel is already working with Rechon Life Science AB, formerly known as Ferring AB, for the manufacture of the company's other late-stage product candidates. Rechon is a well recognized, FDA approved manufacturer of pharmaceutical products.

NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed drugs. The Company's proprietary technology offers, in comparison to conventional oral dosage forms, the potential for faster absorption of drugs into the bloodstream leading to quicker onset of therapeutic effects and possibly reduced first pass liver metabolism, which may result in lower doses.